1.18
price down icon4.84%   -0.06
after-market After Hours: 1.20 0.02 +1.69%
loading
Allogene Therapeutics Inc stock is traded at $1.18, with a volume of 2.09M. It is down -4.84% in the last 24 hours and down -11.28% over the past month. Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.24
Open:
$1.25
24h Volume:
2.09M
Relative Volume:
0.57
Market Cap:
$261.82M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.5566
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-4.07%
1M Performance:
-11.28%
6M Performance:
-30.59%
1Y Performance:
-56.62%
1-Day Range:
Value
$1.17
$1.26
1-Week Range:
Value
$1.17
$1.31
52-Week Range:
Value
$0.8621
$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
Name
Allogene Therapeutics Inc
Name
Phone
(650) 457-2700
Name
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Employee
361
Name
Twitter
@AllogeneTx
Name
Next Earnings Date
2025-05-02
Name
Latest SEC Filings
Name
ALLO's Discussions on Twitter

Compare ALLO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.18 275.13M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
426.00 109.11B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
642.25 68.50B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
434.07 60.25B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
826.28 50.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
186.23 40.44B 447.02M -1.18B -868.57M -6.1812

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-10-25 Downgrade JP Morgan Neutral → Underweight
May-14-25 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
Mar-14-25 Upgrade Citizens JMP Mkt Perform → Mkt Outperform
Aug-08-24 Resumed Oppenheimer Outperform
May-31-24 Initiated Piper Sandler Overweight
Jan-05-24 Downgrade Guggenheim Buy → Neutral
Jan-05-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-08-23 Initiated Citigroup Buy
Jun-26-23 Resumed Oppenheimer Outperform
Mar-21-23 Initiated Bernstein Mkt Perform
Jan-24-23 Upgrade JP Morgan Neutral → Overweight
Jan-06-23 Upgrade Robert W. Baird Neutral → Outperform
Dec-12-22 Downgrade BofA Securities Buy → Underperform
Aug-10-22 Downgrade Raymond James Outperform → Mkt Perform
Jul-15-22 Upgrade Goldman Neutral → Buy
Jun-03-22 Initiated Robert W. Baird Neutral
Feb-28-22 Reiterated B. Riley Securities Buy
Oct-20-21 Initiated Cowen Outperform
Oct-08-21 Downgrade Goldman Buy → Neutral
Oct-08-21 Downgrade Stifel Buy → Hold
Sep-23-21 Upgrade Raymond James Mkt Perform → Outperform
Jun-21-21 Resumed Jefferies Buy
May-20-21 Upgrade Truist Hold → Buy
May-14-21 Initiated B. Riley Securities Buy
Jan-26-21 Upgrade Stifel Hold → Buy
Dec-10-20 Resumed H.C. Wainwright Buy
Nov-24-20 Initiated BofA Securities Buy
Oct-23-20 Initiated RBC Capital Mkts Outperform
Jun-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-29-20 Reiterated H.C. Wainwright Buy
May-19-20 Upgrade ROTH Capital Neutral → Buy
May-15-20 Upgrade Guggenheim Neutral → Buy
May-14-20 Reiterated H.C. Wainwright Buy
May-14-20 Downgrade SunTrust Buy → Hold
Apr-13-20 Initiated SunTrust Buy
Mar-13-20 Initiated H.C. Wainwright Buy
Mar-05-20 Initiated Stifel Hold
Feb-24-20 Initiated Berenberg Hold
Dec-18-19 Initiated JMP Securities Mkt Outperform
Nov-04-19 Initiated Canaccord Genuity Buy
Aug-09-19 Initiated BTIG Research Buy
Jun-05-19 Initiated ROTH Capital Neutral
May-31-19 Initiated Guggenheim Neutral
May-23-19 Initiated Stifel Hold
Mar-29-19 Initiated Piper Jaffray Overweight
View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

pulisher
09:57 AM

How sentiment analysis helps forecast Allogene Therapeutics Inc.2025 Fundamental Recap & Capital Protection Trade Alerts - newser.com

09:57 AM
pulisher
09:35 AM

Allogene to present pivotal trial design for lymphoma therapy at ASH - Investing.com

09:35 AM
pulisher
09:25 AM

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting - The Manila Times

09:25 AM
pulisher
09:24 AM

Allogene to present pivotal trial design for lymphoma therapy at ASH By Investing.com - Investing.com South Africa

09:24 AM
pulisher
08:35 AM

Why Allogene Therapeutics Inc. stock remains on watchlistsQuarterly Performance Summary & Consistent Return Investment Signals - newser.com

08:35 AM
pulisher
08:04 AM

Will Allogene Therapeutics Inc. stock deliver better than expected guidanceGold Moves & Daily Profit Focused Stock Screening - newser.com

08:04 AM
pulisher
05:52 AM

Analyzing Allogene Therapeutics Inc. with multi timeframe chartsJuly 2025 Trends & Community Verified Trade Signals - newser.com

05:52 AM
pulisher
04:40 AM

Using AI based signals to follow Allogene Therapeutics Inc.Profit Target & Free Growth Oriented Trading Recommendations - newser.com

04:40 AM
pulisher
02:31 AM

Published on: 2025-11-02 23:31:58 - newser.com

02:31 AM
pulisher
02:22 AM

Will breakout in Allogene Therapeutics Inc. lead to full recoveryWeekly Market Report & High Accuracy Investment Signals - newser.com

02:22 AM
pulisher
Nov 02, 2025

Chart based analysis of Allogene Therapeutics Inc. trends2025 Top Decliners & Daily Profit Focused Screening - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Using portfolio simulators with Allogene Therapeutics Inc. includedJuly 2025 Big Picture & Risk Managed Investment Entry Signals - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Will Allogene Therapeutics Inc. stock remain a Wall Street favorite2025 Market Outlook & Growth Focused Investment Plans - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Price action breakdown for Allogene Therapeutics Inc.Earnings Overview Report & AI Powered Trade Plan Recommendations - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Risk adjusted return profile for Allogene Therapeutics Inc. analyzedPortfolio Growth Summary & AI Driven Stock Reports - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Applying Elliott Wave Theory to Allogene Therapeutics Inc.Quarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Published on: 2025-11-02 02:58:33 - newser.com

Nov 02, 2025
pulisher
Nov 01, 2025

What candlestick patterns are forming on Allogene Therapeutics Inc.Chart Signals & Community Trade Idea Sharing Platform - newser.com

Nov 01, 2025
pulisher
Nov 01, 2025

Detecting support and resistance levels for Allogene Therapeutics Inc.July 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com

Nov 01, 2025
pulisher
Oct 31, 2025

Allogene Therapeutics (ALLO) to Release Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2025
pulisher
Oct 30, 2025

Allogene Therapeutics (NASDAQ: ALLO) sets Q3 2025 results; webcast at 2 p.m. PT - Stock Titan

Oct 30, 2025
pulisher
Oct 28, 2025

Will Allogene Therapeutics Inc. stock beat EPS estimatesEarnings Risk Report & Free Growth Oriented Trading Recommendations - Fundação Cultural do Pará

Oct 28, 2025

Allogene Therapeutics Inc Stock (ALLO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$37.30
price down icon 0.64%
$28.71
price up icon 0.35%
$101.57
price up icon 8.65%
$103.95
price up icon 0.04%
biotechnology ONC
$311.86
price up icon 0.44%
$186.23
price down icon 1.78%
Cap:     |  Volume (24h):